牛牛AI助理已提取核心訊息
Johnson & Johnson (J&J) has announced a definitive agreement to acquire Ambrx Biopharma, Inc. in an all-cash transaction valued at approximately $2.0 billion. The acquisition, expected to close in the first half of 2024, will enhance J&J's oncology portfolio with Ambrx's proprietary antibody drug conjugates (ADCs) and synthetic biology technology platform. Ambrx's lead product candidate, ARX517, targets metastatic castration-resistant prostate cancer (mCRPC), and the company also has other clinical and preclinical programs for various cancer indications. J&J's Chairman and CEO, Joaquin Duato, discussed the strategic fit of the acquisition at the 42nd Annual Healthcare Conference hosted by JPMorgan, highlighting the potential of Ambrx's ADC technology and the significant market for mCRPC treatments. The transaction is subject to Ambrx shareholder approval, antitrust clearances, and other customary closing conditions. Upon completion, Ambrx's common stock will be delisted from the NASDAQ Global Select Market.
Johnson & Johnson (J&J) has announced a definitive agreement to acquire Ambrx Biopharma, Inc. in an all-cash transaction valued at approximately $2.0 billion. The acquisition, expected to close in the first half of 2024, will enhance J&J's oncology portfolio with Ambrx's proprietary antibody drug conjugates (ADCs) and synthetic biology technology platform. Ambrx's lead product candidate, ARX517, targets metastatic castration-resistant prostate cancer (mCRPC), and the company also has other clinical and preclinical programs for various cancer indications. J&J's Chairman and CEO, Joaquin Duato, discussed the strategic fit of the acquisition at the 42nd Annual Healthcare Conference hosted by JPMorgan, highlighting the potential of Ambrx's ADC technology and the significant market for mCRPC treatments. The transaction is subject to Ambrx shareholder approval, antitrust clearances, and other customary closing conditions. Upon completion, Ambrx's common stock will be delisted from the NASDAQ Global Select Market.
強生公司（J&J）宣佈了一項最終協議，以價值約20億美元的全現金交易收購Ambrx Biopharma, Inc.此次收購預計將於2024年上半年完成，將通過Ambrx的專有抗體藥物偶聯物（ADC）和合成生物學技術平台增強強生的腫瘤學產品組合。Ambrx的主要候選產品 ARX517 針對轉移性去勢抗性前列腺癌（mcRPC），該公司還針對各種癌症適應症還有其他臨床和臨床前項目。強生董事長兼首席執行官華金·杜阿託在摩根大通主辦的第42屆年度醫療保健會議上討論了此次收購的戰略契合度，重點介紹了Ambrx的ADC技術的潛力以及mcRPC治療的巨大市場。該交易須經Ambrx股東批准、反壟斷許可和其他慣例成交條件。完成後，Ambrx的普通股將從納斯達克全球精選市場退市。
強生公司（J&J）宣佈了一項最終協議，以價值約20億美元的全現金交易收購Ambrx Biopharma, Inc.此次收購預計將於2024年上半年完成，將通過Ambrx的專有抗體藥物偶聯物（ADC）和合成生物學技術平台增強強生的腫瘤學產品組合。Ambrx的主要候選產品 ARX517 針對轉移性去勢抗性前列腺癌（mcRPC），該公司還針對各種癌症適應症還有其他臨床和臨床前項目。強生董事長兼首席執行官華金·杜阿託在摩根大通主辦的第42屆年度醫療保健會議上討論了此次收購的戰略契合度，重點介紹了Ambrx的ADC技術的潛力以及mcRPC治療的巨大市場。該交易須經Ambrx股東批准、反壟斷許可和其他慣例成交條件。完成後，Ambrx的普通股將從納斯達克全球精選市場退市。
有用
沒用